Eledon Pharmaceuticals (ELDN) to Post Quarterly Earnings on Thursday

Eledon Pharmaceuticals (NASDAQ:ELDN) will likely be announcing its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect Eledon Pharmaceuticals to post earnings of ($0.1580) per share for the quarter. Parties can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 21, 2026 at 4:00 PM ET.

Eledon Pharmaceuticals (NASDAQ:ELDN) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.11).

Eledon Pharmaceuticals Price Performance

Eledon Pharmaceuticals stock opened at $3.68 on Tuesday. The company has a market cap of $284.06 million, a price-to-earnings ratio of -4.78 and a beta of 0.98. The firm has a 50-day moving average of $3.72 and a 200-day moving average of $3.25. Eledon Pharmaceuticals has a one year low of $1.35 and a one year high of $4.60.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ELDN. Wall Street Zen cut Eledon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Rodman & Renshaw initiated coverage on Eledon Pharmaceuticals in a research note on Tuesday, July 21st. They set a “buy” rating and a $12.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Eledon Pharmaceuticals in a research note on Wednesday, June 24th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $9.67.

Institutional Trading of Eledon Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ELDN. BNP Paribas Financial Markets increased its holdings in shares of Eledon Pharmaceuticals by 143.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,154 shares of the company’s stock worth $31,000 after acquiring an additional 7,166 shares during the last quarter. Millennium Management LLC acquired a new stake in Eledon Pharmaceuticals during the 4th quarter valued at $36,000. Virtu Financial LLC bought a new position in Eledon Pharmaceuticals during the fourth quarter worth $39,000. Cetera Investment Advisers boosted its position in Eledon Pharmaceuticals by 72.9% during the fourth quarter. Cetera Investment Advisers now owns 26,584 shares of the company’s stock worth $40,000 after purchasing an additional 11,207 shares during the period. Finally, Marshall Wace LLP bought a new position in Eledon Pharmaceuticals during the fourth quarter worth $45,000. 56.77% of the stock is owned by institutional investors and hedge funds.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.

Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications.